121 related articles for article (PubMed ID: 26373952)
1. Molecular genetic studies on EGFR, KRAS, BRAF, ALK, PIK3CA, PDGFRA, and DDR2 in primary pulmonary adenoid cystic carcinoma.
Huo Z; Wu H; Li S; Liang Z
Diagn Pathol; 2015 Sep; 10():161. PubMed ID: 26373952
[TBL] [Abstract][Full Text] [Related]
2. Coexistence of EGFR, KRAS, BRAF, and PIK3CA Mutations and ALK Rearrangement in a Comprehensive Cohort of 326 Consecutive Spanish Nonsquamous NSCLC Patients.
Martín Martorell P; Huerta M; Compañ Quilis A; Abellán R; Seda E; Blesa S; Chaves FJ; Dualde Beltrán D; Roselló Keränen S; Franco J; Insa A
Clin Lung Cancer; 2017 Nov; 18(6):e395-e402. PubMed ID: 28550959
[TBL] [Abstract][Full Text] [Related]
3. Primary Pulmonary Mucoepidermoid Carcinoma: Histopathological and Moleculargenetic Studies of 26 Cases.
Huo Z; Wu H; Li J; Li S; Wu S; Liu Y; Luo Y; Cao J; Zeng X; Liang Z
PLoS One; 2015; 10(11):e0143169. PubMed ID: 26575266
[TBL] [Abstract][Full Text] [Related]
4. Molecular alterations in non-small cell lung carcinomas of the young.
VandenBussche CJ; Illei PB; Lin MT; Ettinger DS; Maleki Z
Hum Pathol; 2014 Dec; 45(12):2379-87. PubMed ID: 25288236
[TBL] [Abstract][Full Text] [Related]
5. [Clinicopathological features and prognostic factors of primary pulmonary adenoid cystic carcinoma: a study of 59 cases].
Han J; Gao XZ; Wei JG; Xie YL; Liu YQ; Li WC; Li SL
Zhonghua Bing Li Xue Za Zhi; 2019 Mar; 48(3):204-208. PubMed ID: 30831646
[No Abstract] [Full Text] [Related]
6. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.
Li H; Pan Y; Li Y; Li C; Wang R; Hu H; Zhang Y; Ye T; Wang L; Shen L; Sun Y; Chen H
Lung Cancer; 2013 Jan; 79(1):8-13. PubMed ID: 23098378
[TBL] [Abstract][Full Text] [Related]
7. Analysis of major known driver mutations and prognosis in resected adenosquamous lung carcinomas.
Wang R; Pan Y; Li C; Zhang H; Garfield D; Li Y; Ye T; Hu H; Luo X; Li H; Zhang Y; Zhang J; Zhou X; Shen L; Pao W; Sun Y; Chen H
J Thorac Oncol; 2014 Jun; 9(6):760-8. PubMed ID: 24481316
[TBL] [Abstract][Full Text] [Related]
8. Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung.
Shim HS; Kenudson M; Zheng Z; Liebers M; Cha YJ; Hoang Ho Q; Onozato M; Phi Le L; Heist RS; Iafrate AJ
J Thorac Oncol; 2015 Aug; 10(8):1156-62. PubMed ID: 26200269
[TBL] [Abstract][Full Text] [Related]
9. [Detection of KRAS, BRAF, PIK3CA and EGFR gene mutations in colorectal carcinoma].
Ling Y; Ying JM; Qiu T; Shan L; Guo L; Lü N
Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):590-4. PubMed ID: 23157825
[TBL] [Abstract][Full Text] [Related]
10. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
[TBL] [Abstract][Full Text] [Related]
11. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
[TBL] [Abstract][Full Text] [Related]
12. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).
Barlesi F; Mazieres J; Merlio JP; Debieuvre D; Mosser J; Lena H; Ouafik L; Besse B; Rouquette I; Westeel V; Escande F; Monnet I; Lemoine A; Veillon R; Blons H; Audigier-Valette C; Bringuier PP; Lamy R; Beau-Faller M; Pujol JL; Sabourin JC; Penault-Llorca F; Denis MG; Lantuejoul S; Morin F; Tran Q; Missy P; Langlais A; Milleron B; Cadranel J; Soria JC; Zalcman G;
Lancet; 2016 Apr; 387(10026):1415-1426. PubMed ID: 26777916
[TBL] [Abstract][Full Text] [Related]
13. Sensitive genotyping of somatic mutations in the EGFR, KRAS, PIK3CA, BRAF genes from NSCLC patients using hydrogel biochips.
Emelyanova M; Arkhipova K; Mazurenko N; Chudinov A; Demidova I; Zborovskaya I; Lyubchenko L; Zasedatelev A; Nasedkina T
Appl Immunohistochem Mol Morphol; 2015 Apr; 23(4):255-65. PubMed ID: 25153497
[TBL] [Abstract][Full Text] [Related]
14. Assessment of the clinical application of detecting EGFR, KRAS, PIK3CA and BRAF mutations in patients with non-small cell lung cancer using next-generation sequencing.
Xu X; Yang Y; Li H; Chen Z; Jiang G; Fei K
Scand J Clin Lab Invest; 2016 Sep; 76(5):386-92. PubMed ID: 27215271
[TBL] [Abstract][Full Text] [Related]
15. Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers.
Lee SY; Kim MJ; Jin G; Yoo SS; Park JY; Choi JE; Jeon HS; Cho S; Lee EB; Cha SI; Park TI; Kim CH; Jung TH; Park JY
J Thorac Oncol; 2010 Nov; 5(11):1734-40. PubMed ID: 20881644
[TBL] [Abstract][Full Text] [Related]
16. Screening for major driver oncogene alterations in adenosquamous lung carcinoma using PCR coupled with next-generation and Sanger sequencing methods.
Shi X; Wu H; Lu J; Duan H; Liu X; Liang Z
Sci Rep; 2016 Feb; 6():22297. PubMed ID: 26923333
[TBL] [Abstract][Full Text] [Related]
17. Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience.
Sholl LM; Aisner DL; Varella-Garcia M; Berry LD; Dias-Santagata D; Wistuba II; Chen H; Fujimoto J; Kugler K; Franklin WA; Iafrate AJ; Ladanyi M; Kris MG; Johnson BE; Bunn PA; Minna JD; Kwiatkowski DJ;
J Thorac Oncol; 2015 May; 10(5):768-777. PubMed ID: 25738220
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Next-Generation Sequencing, Quantitative PCR, and Sanger Sequencing for Mutation Profiling of EGFR, KRAS, PIK3CA and BRAF in Clinical Lung Tumors.
Gao J; Wu H; Shi X; Huo Z; Zhang J; Liang Z
Clin Lab; 2016; 62(4):689-96. PubMed ID: 27215089
[TBL] [Abstract][Full Text] [Related]
19. MET and EGFR mutations identified in ALK-rearranged pulmonary adenocarcinoma: molecular analysis of 25 ALK-positive cases.
Boland JM; Jang JS; Li J; Lee AM; Wampfler JA; Erickson-Johnson MR; Soares I; Yang P; Jen J; Oliveira AM; Yi ES
J Thorac Oncol; 2013 May; 8(5):574-81. PubMed ID: 23449277
[TBL] [Abstract][Full Text] [Related]
20. Low incidence of KRAS, BRAF, and PIK3CA mutations in adenocarcinomas of the ampulla of Vater and their prognostic value.
Kwon MJ; Kim JW; Jung JP; Cho JW; Nam ES; Cho SJ; Kim JS; Park HR; Min SK; Seo J; Min KW; Kim DH; Jeon JY
Hum Pathol; 2016 Apr; 50():90-100. PubMed ID: 26997442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
